EUVIMEDEUVIMED entdecken
Crossref

Omeprazole-cisapride combination for gastroparesis following radical gastrectomy for gastric cancer: An efficacy and safety analysis

Shan-Ling Zhu, Qian Gao, Yang Liu, Kun-Peng Cheng

World Journal of Gastrointestinal Surgery · 27.11.2026 · 18 (11)

DOI: 10.4240/wjgs.122614 ↗

Kurz gefasst

Fachartikel in der Zeitschrift World Journal of Gastrointestinal Surgery, online erschienen am 27.11.2026. Verfasst von Shan-Ling Zhu und 3 weiteren Autor:innen. Die Arbeit nennt 28 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND The management of gastroparesis (GP) following radical gastrectomy (RGE) for gastric cancer (GC) remains challenging, and treatment optimization is needed because current therapeutic approaches have limited efficacy. AIM To investigate the clinical efficacy and safety of omeprazole (OME) combined with cisapride (CIS) in the treatment of GP after RGE in patients with GC. METHODS A total of 198 patients with post-RGE GP were retrospectively enrolled from September 2020 to September 2025. Patients were grouped according to treatment regimen: 92 patients receiving OME constituted the control group, and 106 patients receiving OME plus CIS comprised the research group. Outcomes included clinical efficacy, symptom improvement assessed using the GP Cardinal Symptom Index, gastrointestinal function recovery (time to bowel sound recovery, nasogastric tube removal, and resumption of a normal diet), gastrointestinal hormone levels (gastrin and motilin), and safety (diarrhea, abdominal pain, headache/dizziness, palpitations, and nausea). Factors influencing treatment efficacy were subsequently evaluated. RESULTS The research group showed a significantly higher total effective rate than the control group. Following treatment, GP Cardinal Symptom Index scores across all domains were lower, the time to bowel sound recovery, nasogastric tube removal, and normal diet resumption was shorter, and gastrin and motilin levels were higher in patients receiving the combination therapy. The incidence of total adverse reactions was comparable between the two groups. Tumor-node-metastasis staging, baseline motilin level, and treatment regimen were independent factors affecting treatment efficacy. CONCLUSION OME combined with CIS is effective for treating GP after RGE for GC without increasing the overall incidence of adverse reactions. Additionally, stage IIB-III disease, baseline motilin < 309 mg/L, and treatment with OME alone are associated with an increased risk of treatment inefficacy.

Zitieren

APA

Zhu, S., Gao, Q., Liu, Y., & Cheng, K. (2026). Omeprazole-cisapride combination for gastroparesis following radical gastrectomy for gastric cancer: An efficacy and safety analysis. World Journal of Gastrointestinal Surgery, 18(11). https://doi.org/10.4240/wjgs.122614

Vancouver

Zhu S, Gao Q, Liu Y, Cheng K. Omeprazole-cisapride combination for gastroparesis following radical gastrectomy for gastric cancer: An efficacy and safety analysis. World Journal of Gastrointestinal Surgery. 2026;18(11). doi:10.4240/wjgs.122614

BibTeX
@article{Zhu2026,
  author = {Zhu, Shan-Ling and Gao, Qian and Liu, Yang and Cheng, Kun-Peng},
  title = {Omeprazole-cisapride combination for gastroparesis following radical gastrectomy for gastric cancer: An efficacy and safety analysis},
  journal = {World Journal of Gastrointestinal Surgery},
  year = {2026},
  volume = {18},
  number = {11},
  doi = {10.4240/wjgs.122614}
}
Kostenlos starten →